Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 27, Issue 9, 2005, Pages 617-622

  Lee, S ^a   Koo, H N ^b   Lee, Byung Ho ^b  

^a Sangmyung University   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

384 Well assay; DNA damage; Nonisotopic; PARP; PARP inhibition

Indexed keywords

3,4 DIHYDRO 5 [4 (1 PIPERIDUNYL)BUTOXY] 1(2H) ISOQUINOLINONE; 6(5H) PHENANTHRIDINONE; KR 33152; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BIOTINYLATION; COLORIMETRY; COST EFFECTIVENESS ANALYSIS; ENZYME ASSAY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; INTERMETHOD COMPARISON; METHODOLOGY; REPRODUCIBILITY; SCREENING; SENSITIVITY ANALYSIS; VALIDATION PROCESS;

BIOTINYLATION; COLORIMETRY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; INHIBITORY CONCENTRATION 50; MINIATURIZATION; NAD; POLY(ADP-RIBOSE) POLYMERASES;

EID: 29244458197     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2005.27.9.939334     Document Type: Article

References (23)

1. Ame, J.C., Spenlehauer, C., de Murcia, G. The PARP superfamily. Bioessays 2004, 26: 882-93.
2. Huber, A., Bai, P., de Murcia, J.M., de Murcia, G. PARP-1, PARP-2 and ATM in the DNA damage response: Functional synergy in mouse development. DNA Repair 2004, 3: 1103-8.
3. de Murcia, G., de Murcia, J.M. Poly(ADP-ribose) polymerase: A molecular nick-sensor. Trends Biochem Sci 1994, 19: 172-6.
4. de Murcia, G., Schreiber, V., Molinete, M., et al. Structure and function of poly(ADP-ribose) polymerase. Mol Cell Biochem 1994, 138: 15-24.
5. de Murcia, J.M., Niedergang, C., Trucco, C., et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc Natl Acad Sci USA 1997, 94: 7303-7.
6. Szabo, G., Liaudet, L., Hagl, S., Szabo, C. Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res 2004, 61: 471-80.
7. Schraufstatter, I.U., Hyslop, P.A., Hinshaw, D.B., Spragg, R.G., Sklar, L.A., Cochrane, C.G. Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase. Proc Natl Acad Sci USA 1986, 83: 4908-12.
8. Szabo, C., Dawson, V.L. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 1998, 19: 287-98.
9. Thiemermann, C., Bowes, J., Myint, P.P., Vane, J.R. Inhibition of the activity of poly(ADP-ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 1997, 94: 679-83.
10. Zhang, J., Lautar, S., Huang, S., Ramsey, C., Cheung, A., Li, J.H. GPI 6150 prevents H(2)O(2) cytotoxicity by inhibiting poly(ADP-ribose) polymerase. Biochem Biophys Res Commun 2000, 278: 590-8.
11. Virag, L., Szabo, C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002, 54: 375-429.
12. Southan, G.J., Szabo, C. Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem 2003, 10: 321-40.
13. Tentori, L., Portarena, I., Graziani, G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002, 45: 73-85.
14. Li, J.H., Serdyuk, L., Ferraris, D.V., et al. Synthesis of substituted 5[H]phenanthridin-6-ones as potent poly(ADP-ribose)polymerase-1 (PARP1) inhibitors. Bioorg Med Chem Lett 2001, 11: 1687-90.
15. Burbaum, J.J., Sigal, N.H. New technologies for high-throughput screening. Curr Opin Chem Biol 1997, 1: 72-8.
16. Ferraris, D., Ko, Y.S., Pahutski, T., et al. Design and synthesis of poly ADP-rihose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries. J Med Chem 2003, 46:3138-51.
17. Zhang, J.-H., Chung, T.D.Y., Oldenburg, K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999, 4: 67-73.
18. Banasik, M., Komura, H., Shimoyama, M., Ueda, K. Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 1992, 267: 1569-75.
19. Takahashi, K., Pieper, A.A., Croul, S.E., Zhang, J., Snyder, S.H., Greenberg, J.H. Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia. Brain Res 1999, 829: 46-54.
20. Moroni, F., Meli, E., Peruginelli, F., et al. Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia. Cell Death Differ 2001, 8: 921-32.
21. Dillon, K.J., Smith, G.C., Martin, N.M. A FlashPlate assay for the identification of PARP-1 inhibitors. J Biomol Screen 2003, 8: 347-52.
22. Putt, K.S., Hergenrother, P.J. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): Application to the high-throughput screening of small molecules as potential inhibitors. Anal Biochem 2004, 326: 78-86.
23. Brown, J.A., Marala, R.B. Development of a high-throughput screening-Amenable assay for human poly(ADP-ribose) polymerase inhibitors. J Pharmacol Toxicol Methods 2002, 47: 137-41.